<DOC>
	<DOCNO>NCT00096187</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , pemetrexed disodium , work different way stop tumor cell divide stop grow die . PURPOSE : This phase II trial study well pemetrexed disodium work treat patient recurrent persistent low-risk gestational trophoblastic tumor molar pregnancy .</brief_summary>
	<brief_title>Pemetrexed Disodium Treating Patients With Recurrent Persistent Low-Risk Gestational Trophoblastic Tumor After Molar Pregnancy</brief_title>
	<detailed_description>OBJECTIVES : - Determine activity pemetrexed disodium salvage therapy patient persistent recurrent low-risk post-molar gestational trophoblastic tumor fail prior dactinomycin methotrexate . - Determine toxicity drug patient . OUTLINE : This multicenter study . Patients receive pemetrexed disodium IV 10 minute day 1 . Courses repeat every 21 day absence unacceptable toxicity disease progression tumor marker level ( human chorionic gonadotropin [ hCG ] ) become normal . Patients receive 2 additional course beyond attainment normal hCG . Beginning 7 day continue 3 week last dose pemetrexed disodium , patient also receive oral folic acid daily cyanocobalamin ( vitamin B_12 ) intramuscularly every 9 week . Patients follow every 2 week 2 month monthly 10 month . PROJECTED ACCRUAL : Approximately 17-55 patient accrue study within 20-50 month .</detailed_description>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis lowrisk postmolar gestational trophoblastic tumor , define 1 following : Increasing human chorionic gonadotropin ( hCG ) level ≥ 3 consecutive measurement take ≥ 2week period Less 10 % decrease hCG level 4 measurement take ≥ 3week period Persistent recurrent disease Histologically confirm complete partial mole initial evacuation Prior pregnancy ≤ 12 month ago No histologically confirm choriocarcinoma placental site trophoblastic tumor initial evacuation Failed 1 prior dactinomycin methotrexate therapy ( without leucovorin calcium ) WHO score 26 No evidence metastatic disease , except lung vagina , physical exam , chemistry , chest Xray , ultrasound No liver , spleen , brain , kidney , gastrointestinal tract metastases No 8 metastatic lesion PATIENT CHARACTERISTICS : Age Any age Performance status GOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Granulocyte count ≥ 1,500/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGOT ≤ 3 time ULN Alkaline phosphatase ≤ 3 time ULN Renal Creatinine ≤ 1.5 mg/dL Creatinine clearance ≥ 45 mL/min Other Not pregnant nursing Fertile patient must use effective contraception 3 month study participation No significant infection No invasive malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent prophylactic filgrastim ( GCSF ) unless recurrent neutropenic complication No concurrent prophylactic thrombopoietic agent unless recurrent grade 4 thrombocytopenia Chemotherapy See Disease Characteristics At least 7 day since prior dactinomycin methotrexate ( without leucovorin calcium ) recover No prior pemetrexed disodium No prior chemotherapy Endocrine therapy Not specify Radiotherapy At least 14 day since prior radiotherapy recover No prior radiotherapy ≥ 25 % bone marrow Surgery Recovered prior surgery Other No nonsteroidal antiinflammatory drug salicylates 2 day ( 5 day drug long halflife ) , , 2 day pemetrexed disodium administration Concurrent lowdose aspirin ( ≤ 325 mg/day ) allow</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>low risk metastatic gestational trophoblastic tumor</keyword>
	<keyword>recurrent gestational trophoblastic tumor</keyword>
	<keyword>nonmetastatic gestational trophoblastic tumor</keyword>
</DOC>